For US Healthcare Professionals
For US Healthcare Professionals
TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
VOYAGE 1: MAJOR SECONDARY ENDPOINT AT WEEK 16 (NORTH AMERICAN ANALYSIS)
†P<0.001 vs Humira®.
The same patients may not have responded at each time point.
‡PASI 75 at Weeks 24 and 48 were prespecified exploratory endpoints that were not adjusted for multiplicity; P values were considered nominal.
VOYAGE 2: MAJOR SECONDARY ENDPOINT AT WEEK 16 (NORTH AMERICAN ANALYSIS)
§P<0.001 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
*PASI 75=Proportion of patients who achieved 75% or more reduction (or improvement) in PASI score from baseline.
VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 16, 24, AND 48 (NORTH AMERICAN ANALYSIS)
*P<0.001 vs Humira®.
The same patients may not have responded at each time point.
VOYAGE 2: MAJOR SECONDARY ENDPOINTS AT WEEKS 16 AND 24 (NORTH AMERICAN ANALYSIS)
†P<0.001 vs Humira®.
‡P=0.003 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 16, 24, AND 48 (NORTH AMERICAN ANALYSIS)
*P<0.001 vs Humira®.
The same patients may not have responded at each time point.
VOYAGE 2: MAJOR SECONDARY ENDPOINTS AT WEEKS 16 AND 24 (NORTH AMERICAN ANALYSIS)
†P<0.027 vs Humira®.
‡P=0.005 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 24 AND 48 (NORTH AMERICAN ANALYSIS)
*P<0.001 vs Humira®.
The same patients may not have responded at each time point.
VOYAGE 2: MAJOR SECONDARY ENDPOINT AT WEEK 24 (NORTH AMERICAN ANALYSIS)
†P=0.005 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
VOYAGE 1: PRESPECIFIED EXPLORATORY ENDPOINT AT WEEKS 24 AND 48 (NORTH AMERICAN ANALYSIS)
PASI 100 was a prespecified exploratory endpoint that was not adjusted for multiplicity; P values were considered nominal.
The same patients may not have responded at each time point.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 that used US-licensed Humira®.
*PASI 100=Proportion of patients who achieved 100% reduction (or improvement) in PASI score from baseline.
VOYAGE 1: MAJOR SECONDARY ENDPOINT AT WEEK 16 (NORTH AMERICAN ANALYSIS)
The same patients may not have responded at each time point.
‡PASI 75 at Weeks 24 and 48 were prespecified exploratory endpoints that were not adjusted for multiplicity; P values were considered nominal.
VOYAGE 2: MAJOR SECONDARY ENDPOINT AT WEEK 16 (NORTH AMERICAN ANALYSIS)
§P<0.001 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
*PASI 75=Proportion of patients who achieved 75% or more reduction (or improvement) in PASI score from baseline.
VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 16, 24, AND 48 (NORTH AMERICAN ANALYSIS)
The same patients may not have responded at each time point.
VOYAGE 2: MAJOR SECONDARY ENDPOINTS AT WEEKS 16 AND 24 (NORTH AMERICAN ANALYSIS)
†P<0.001 vs Humira®.
‡P=0.003 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 16, 24, AND 48 (NORTH AMERICAN ANALYSIS)
The same patients may not have responded at each time point.
VOYAGE 2: MAJOR SECONDARY ENDPOINTS AT WEEKS 16 AND 24 (NORTH AMERICAN ANALYSIS)
†P<0.027 vs Humira®.
‡P=0.005 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
VOYAGE 1: MAJOR SECONDARY ENDPOINTS AT WEEKS 24 AND 48 (NORTH AMERICAN ANALYSIS)
The same patients may not have responded at each time point.
VOYAGE 2: MAJOR SECONDARY ENDPOINT AT WEEK 24 (NORTH AMERICAN ANALYSIS)
†P=0.005 vs Humira®.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 and 41 North American sites (United States=31, Canada=10) from VOYAGE 2 that used US-licensed Humira®.
VOYAGE 1: PRESPECIFIED EXPLORATORY ENDPOINT AT WEEKS 24 AND 48 (NORTH AMERICAN ANALYSIS)
PASI 100 was a prespecified exploratory endpoint that was not adjusted for multiplicity; P values were considered nominal.
The same patients may not have responded at each time point.
Based on the results of an analysis of 38 North American sites (United States=27, Canada=11) from VOYAGE 1 that used US-licensed Humira®.
*PASI 100=Proportion of patients who achieved 100% reduction (or improvement) in PASI score from baseline.
Humira® is a registered trademark of AbbVie Inc.
References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.